BRENDA E RICHARDSON, M.D.
Osteopathic Medicine at Washington St, Gloucester, MA

2010004, Feb 25, 2010

Aug 20, 2008

12/195143

Kenneth C. Slater - Manchester MA, US
Brenda E. Richardson - Manchester MA, US
Scott M. Connors - Methuen MA, US
Wei-wei Chang - Boston MA, US

A61K 31/485, A61K 31/554, A61K 31/4709

51421113, 514282, 514305

A method of reducing the concentration of a chemical or drug substance in the blood plasma that targets the same or similar receptors as the normal neurotransmitters in the central or peripheral nervous system includes titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood immediately before the end of the dosing period, and providing a plurality of subsequent dosing periods where each subsequent dosing period requires administration of a dosing amount of the chemical or drug substance and titrating of the peak concentration and the lowest concentration level to ensure that the lowest concentration level of the chemical or drug substance in the blood plasma for the subsequent dosing period is decreased by not more than five percent of the lowest concentration level of the previous dosing period and where the plurality of dosing periods added together extends the method for seventy days or more.

2012020, Aug 16, 2012

Mar 23, 2012

13/428380

Kenneth C. Slater - Manchester MA, US
Brenda E. Richardson - Manchester MA, US
Scott M. Connors - Methuen MA, US
Wei-wei Chang - Boston MA, US

A61K 31/4748, A61P 25/36

514279

A method of reducing the concentration of a chemical or drug substance in the blood plasma comprising titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood immediately before the end of the dosing period, and providing a plurality of subsequent dosing periods where each subsequent dosing period requires administration of a dosing amount of the chemical or drug substance and titrating of the peak concentration and the lowest concentration level to ensure that the lowest concentration level of the chemical or drug substance in the blood plasma for the subsequent dosing period is decreased by not more than five percent of the lowest concentration level of the previous dosing period and where the plurality of dosing periods added together is seventy days or more.

2008019, Aug 21, 2008

Feb 15, 2007

11/675560

Kenneth C. Slater - Manchester by the Sea MA, US
Brenda E. Richardson - Manchester by the Sea MA, US

A61K 31/439, A61P 25/30

424 103, 424 101, 514 1, 514282

This invention relates to use of an opioid receptor agonist in microdose quantities to reduce or eliminate the withdrawal symptoms associated with discontinuing drug use. The dosage of the agonist is reduced over an extended period of time.